Hace casi medio siglo se descubrieron las antraciclinas; estas son antibióticos Palabras clave: Cardiotoxicidad de antraciclinas; Miocardiopatía por. cardiotoxicidad, es una complicación del tratamiento antineoplásico, la cual Palabras clave: Cardiotoxicidad, Antraciclinas, Ecocardiograma, Strain rate. PURPOSE: We determined the frequency of and risk factors for congestive heart failure following treatment for Wilms’ tumor that included doxorubicin.
|Published (Last):||1 November 2016|
|PDF File Size:||5.75 Mb|
|ePub File Size:||18.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
CARDIOTOXICIDAD POR DOXORRUBICINA EN CANINOS by Maria Mejia on Prezi
Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Approaches to risk-stratifying cancer patients for venous thromboembolism. Cardiac surgery in patients with previous carcinoma of the breast and mediastinal irradiation: Ischemic heart disease associated with vincristine and doxorubicin chemotherapy. Halliwell B, Gutteridge J. Introduction Anthracyclines are cytostatic antibiotics discovered almost half a century ago that exert their action through inhibition of topoisomerase II.
Longitudinal cardioyoxicidad of early and late anthracycline cardiotoxicity in children with AML. Antonio Ruggiero 17 Estimated H-index: Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen.
Etoposide-related cardiotoxicity in a child with haemophagocytic lymphohistiocytosis. What is QT interval prolongation?
With the improved survival from different oncologic diseases we are witnessing more cases of chemotherapy-induced cardiotoxicity and the advent of new anticancer drugs poses several challenges for the cardiologist, highlighting the importance of a deep knowledge of the main mechanisms inducing this toxicity.
Anthracycline toxicity seems to be a multistep and multifactorial condition, with complex pathophysiology and requiring a cardiotoxicidd approach.
Los farmacos mas utilizados de este grupo son la daunorrubicina leucemias cardiotoxicidd y linfomas y la doxorrubicina leucemias agudas, linfomas y distintos tumores solidos.
Lapatinib and breast cancer: A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection. Reversibility of trastuzumab-related cardiotoxicity: Anticancer drugs and cardiotoxicity: Cardiac side-effects of cancer chemotherapy.
Chemotherapy-induced cardiotoxicity is usually classified in two groups according to the cellular damage induced by these drugs.
Cardiotoxicity of chemotherapeutic agents: Current and emerging treatment strategies for cutaneous T-cell lymphoma. Free radicals in biology and medicine.
[Anthracycline-induced cardiotoxicity: report of fatal cases].
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and anntraciclinas IV non-small cell lung cancer. Cardiac disturbances during the administration of taxol.
J Mol Cell Cardiol. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Meta-analysis of vascular and neoplastic events associated with tamoxifen. Molecularly targeted oncology therapeutics and prolongation of the QT interval. Octavia y, Tocchetti C, Gabrielson K, et al.
Doxorubicin administration by continuous infusion is not cardioprotective: Anthracycline cardiotoxicity; Chemotherapy cardiomyopathy; Doxorubicin cardiomyopathy; Spain. Superior detection of cardiotoxicity during chemotherapy using biomarkers.
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Spanish pdf Article in xml format Article references How to cite this article Automatic translation Send this article by e-mail. Eur J Heart Fail.
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Type II chemotherapy-related cardiac dysfunction: